Clinical Research News: Action plan developed to enhance enrollment in acute stroke trials

Clinical trials are a critical step in improving treatments and care for acute stroke patients, and enrolling a large and diverse patient population in trials helps push research forward.

At the Stroke Treatment Academic Industry Roundtable XII meeting in March, stroke physicians, researchers, industry representatives and members of the National Institute of Neurological Disorders and Stroke and the U.S. Food and Drug Administration discussed the current status of enrolling patients in acute stroke trials and the most pressing issues impacting enrollment.

The meeting's review and recommendations were published in the journal Stroke, led by corresponding author Joseph Broderick, MD, professor in the University of Cincinnati’s Department of Neurology and Rehabilitation Medicine in the College of Medicine, director of the UC Gardner Neuroscience Institute and a UC Health physician.

“While we may have a lot of good ideas, none of them are going to get tested without recruitment," Broderick told Clinical Research News.

Due to the time sensitive nature of treatments being tested for acute stroke, Broderick said emergency consent procedure is one area in need of improvement. The published recommendation is for centralizing some of the exception from informed consent workload and using national data in conjunction with local community events and including patients and family members in trial planning.

“This past year we added stroke survivors to our working groups that help design future trials,” Broderick said. They’re engaged with an assortment of questions, among them: Does this make sense to you? Do you think this would be worthwhile? How would you present this trial opportunity to a potential patient?"

Read the Clinical Research News article.

Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati


Related Stories


WLWT: UC hosts RESET epilepsy trial

May 3, 2023

WLWT spoke with the University of Cincinnati's Brandon Foreman about a clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.